180186-94-1

基本信息
(+)2,2'-亞甲基雙(3Α,8Α-二氫-8H-茚并[1,2--D]噁唑
2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-茚苯[1,2-D]并惡唑
(+)-2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-茚苯[1,2-D]并噁唑
(+)-2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-茚并[1,2-D]噁唑]
(+)-2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-吲哚[1,2-D]惡唑]
(+)-2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-茚并[1,2-D]惡唑]
(+)-2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-茚苯[1,2-D]并惡唑
(3AR,3'AR,8AS,8'AS)-2,2'-亞甲基雙[3A,8A-二氫-8H-茚并[1,2-D]惡唑]
3AR-[2(3′AR*,8′AS*),3′AΒ,8′AΒ]]-(+)-2,2′-亞甲基雙[3A,8A-二氫-8H-茚并[1,2-]噁唑
[3aR-[2(3′aR*,8′aS*),3′aβ,8′aβ]]-(+)-2,2′-Methylenebis[3a,8a
Bis((3aR,8aS)-8,8a-dihydro-3aH-indeno[1,2-d]oxazol-2-yl)Methane
(+)-2,2-METHYLENEBIS[(3AR,8AS)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE
(+)-2,2'-METHYLENEBIS[(3AR,8AS)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE]
(+)-2,2'-Methylenebis[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole] >
(+)-2,2'-Methylenebis[(3AR,8AS)-3A,8A-Dihydro-8H-Indeno[1,2-D]Oxazole],98%
(-)-2,2''-METHYLENEBIS-[(3AR,8AS)-3A,8A-DIHYDRO-8H-INDENO[1,2-D]OXAZOLE] EP
(3aR,3'aR,8aS,8'aS)-2,2'-Methylenebis[3a,8a-dihydro-8H-indeno[1,2-d]oxazole]
8H-Indeno[1,2-d]oxazole, 2,2'-methylenebis[3a,8a-dihydro-, (3aR,3'aR,8aS,8'aS)-
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表

136030-00-7

10344-69-1
![(+)-2,2'-亞甲基雙[(3AR,8AS)-3A,8A-二氫-8H-茚苯[1,2-D]并惡唑](/CAS/GIF/180186-94-1.gif)
180186-94-1
向3 L圓底燒瓶中加入丙二酰亞胺二乙酯二鹽酸鹽(25.8 g,0.112 mol,1.0當(dāng)量)和二甲基甲酰胺(DMF)(320 mL)。將混合物置于冰浴中冷卻。在20分鐘內(nèi),向該懸浮液中分批加入(1R,2S)-1-氨基-2-茚醇(40 g,0.268 mol,2.4當(dāng)量)。隨后移除冰浴,使反應(yīng)混合物緩慢升溫至室溫,期間反應(yīng)產(chǎn)物逐漸從溶液中析出。在室溫下持續(xù)攪拌4天后,進(jìn)行過濾操作。將所得白色固體懸浮于二氯甲烷(CH2Cl2,450 mL)中。接著,依次用水(260 mL)和鹽水(260 mL)洗滌混合物。有機(jī)層經(jīng)無水硫酸鈉(Na2SO4)干燥后,過濾并濃縮,得到灰白色固體。將該固體在真空條件下干燥過夜,最終獲得23.9 g(收率65%)目標(biāo)產(chǎn)物雙(惡唑啉)(4)。產(chǎn)物經(jīng)1H NMR(300 MHz,CDCl3)表征:δ 7.45(m,2H,Ar-H);7.27-7.21(m,6H,Ar-H);5.56(d,J = 7.9 Hz,2H,N-CH);5.34(m,2H,O-CH);3.39(dd,J = 7.0, 18.0 Hz,2H,Ar-CHH);3.26(s,2H,-CH2-O);3.16(d,J = 18.0 Hz,2H,Ar-CHH)。核磁共振數(shù)據(jù)與文獻(xiàn)WO 00/15599報(bào)道一致。
參考文獻(xiàn):
[1] Organic Letters, 2017, vol. 19, # 8, p. 2150 - 2153
[2] Journal of the American Chemical Society, 2018, vol. 140, # 1, p. 139 - 142
[3] Patent: WO2004/96764, 2004, A1. Location in patent: Page 38
[4] Organic Letters, 2006, vol. 8, # 3, p. 539 - 542
報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
2025/05/22 | M1401 | (+)-2,2'-亞甲基雙[(3aR,8aS)-3a,8a-二氫-8H-茚并[1,2-d]惡唑] (+)-2,2'-Methylenebis[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole] | 180186-94-1 | 100mg | 145元 |
2025/05/22 | M1401 | (+)-2,2'-亞甲基雙[(3aR,8aS)-3a,8a-二氫-8H-茚苯[1,2-d]并惡唑 (+)-2,2'-Methylenebis[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole] | 180186-94-1 | 500MG | 445元 |
2016/03/17 | M1401 | (+)-2,2'-亞甲基雙[(3aR,8aS)-3a,8a-二氫-8H-茚苯[1,2-d]并惡唑 (+)-2,2'-Methylenebis[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole] | 180186-94-1 | 1G | 1510元 |